Work

Phase I trial of the multi-drug resistance (MDR) Protein-1 (MRP-1) modulating agent sulindac (S) plus epirubicin (E) in patients (pts) with advanced cancer

Year: 2004

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2004.22.14_suppl.2129

Authors: M. O' Leary, R. O' Connor, S. Roy, J. Ballot, W. Ooi, D. Fennelly, L. Sheehan, C. Collins, M. Clynes, J. Crown

Institutions: St. Vincent's University Hospital, Dublin City University

Language: English

Topic: Drug Transport and Resistance Mechanisms

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2261327409

Cites:

Cited by: 2

Related to: 10